GlassScriptPhysician profile
Gerald L Shulman
NPI 1235112319
$193,900.56
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79K · 2020: $28K · 2021: $28K · 2022: $39K · 2023: $11K · 2024: $7,941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Food and Beverage: $41.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,740.75 |
| Food and Beverage | $41.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Research & Development, LLC | $93,914.94 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $43,295.74 | 2019-2022 | |
| Gilead Sciences, INC. | $18,409.30 | 2019-2020 | |
| Astrazeneca Uk Limited | $10,740.00 | 2020-2024 | |
| Astrazeneca Ab | $9,480.00 | 2019-2020 | |
| Esperion Therapeutics, INC. | $8,245.00 | 2022-2024 | Nexlizet, Nexletol |
| Novo Nordisk INC | $6,204.58 | 2019-2024 | Ozempic, Rybelsus |
| Theratechnologies INC. | $2,000.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $1,611.00 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Shulman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.